NCT01258712

Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Randomized, Placebo-controlled Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Chugai Pharma Taiwan · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase III study to evaluate efficacy and safety of Tocilizumab in patients with Rheumatoid Arthritis.

Conditions

• Rheumatoid Arthritis (RA)

Interventions

Type	Name	Description
DRUG	Tocilizumab + methotrexate(MTX)	Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
DRUG	Tocilizumab placebo + methotrexate(MTX)	Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week

Timeline

• Start date: 2010-12-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2010-12-13
• Last updated: 2012-12-13

Locations

12 sites across 1 country: Taiwan